OncoSec Medical Announces October Events Agenda

Company Also Provides Update on Data Presented at ESMO 2014 Congress 

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will attend or present at three events in October. The company’s agenda includes a number of high-profile scientific and investment conferences, following a recent presentation of data at the ESMO 2014 Congress.

Robert H. Pierce, M.D., Chief Scientific Officer said, “It was a great opportunity to be able to present our latest correlative data on IL-12 electroporation at ESMO. In this presentation, we were able to show how our transcriptional analysis of treated melanoma patient samples mirrors what we have seen in the B16 syngeneic mouse tumor model. This gives us increased confidence that our model truly reflects what is happening in patients. These data, which demonstrate that intratumoral IL-12 electroporation is generating a systemic anti-tumor immune response, provide strong support for moving forward with a combination of intratumoral IL-12 electroporation and an anti-PD-1 therapeutic.”

For more information on data presented at the ESMO 2014 Congress, please contact OncoSec Medical directly via the information below.

Cancer Vaccines and Gene Therapy Meeting
Tu Diep, Vice President of Operations, will present a discussion titled “Clinical Response and Immune Correlates of Intratumoral Electroporation of IL-12 in Advanced Melanoma” at the 2nd Annual Cancer Vaccines and Gene Therapy (CVGT) Meeting. The meeting will take place October 6-7, 2014 at The Desmond in Malvern, Pennsylvania. Mr. Diep’s presentation will begin at 11 AM EST on Tuesday, October 7.

The 2nd Annual CVGT Meeting will bring together important field leaders to present and discuss the latest approaches and technologies used to develop promising anti-cancer therapeutics. The agenda will feature presentations and interactive discussions designed to maximize the potential of cancer immunotherapeutics and implement strategies to ensure successful cancer vaccine development. For more information, please visit http://www.ngtcancervaccines.com/index.html

BIO Investor Forum
Punit Dhillon, President and CEO, will present a corporate overview of the company at the 13th Annual BIO Investor Forum, taking place October 7-8, 2014 at The Palace Hotel in San Francisco, California. Mai H. Le, M.D., OncoSec’s newly appointed Chief Medical Officer, will also be attending this industry-leading event. The presentation is scheduled to begin at 9 AM PST on Tuesday, October 7 in the Presidio Room.

One hour after the presentation, a webcast will be made available via the following link: http://www.veracast.com/webcasts/bio/investorforum2014/11102154601.cfm

An archived version of the webcast will be available in the “Events” section of the OncoSec web page at http://www.oncosec.com

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies like OncoSec Medical. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and one-on-one partnering meetings, as part of an agenda designed to facilitate meaningful discussion among investors and industry leaders. For more information, please visit http://www.bio.org/events/conferences/13th-annual-bio-investor-forum

Biotech CEO Meeting
Mr. Dhillon will participate in the 27th Annual Biotech CEO Meeting, taking place October 12-14, 2014 at The Montage in Laguna Beach, California.

The 27th Annual Biotech CEO Meeting will bring together a select group of biotech and pharma CEOs to take part in a unique and interactive networking event. The meeting is designed to provide a comprehensive platform for open discussion, debate and problem solving among CEO peers.

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:
OncoSec Medical Inc.
Jordyn Kopin, 855-662-6732
Public Relations:
Dian Griesel, Int’l.
Laura Radocaj, 212-825-3210

Source: OncoSec Medical Inc.